Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myocardial Fibrosis - Overview
Myocardial Fibrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocardial Fibrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocardial Fibrosis - Companies Involved in Therapeutics Development
Evotec SE
Galectin Therapeutics Inc
Haya Therapeutics
Invivosciences Inc
Lead Discovery Center GmbH
Limil BioSciences Inc
MandalMed Inc
NovoMedix LLC
Palatin Technologies Inc
Pharmaxis Ltd
TRACON Pharmaceuticals Inc
Vectus Biosystems Ltd
Myocardial Fibrosis - Drug Profiles
Antisense Oligonucleotides for Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belapectin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Tissue Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GYY-4137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-922 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-5028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN1-Ab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXS-5153A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXS-5338K - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXS-5382A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPI-2049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRC-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-0004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myocardial Fibrosis - Dormant Projects
Myocardial Fibrosis - Discontinued Products
Myocardial Fibrosis - Product Development Milestones
Featured News & Press Releases
Oct 08, 2019: Publication that demonstrates reversal of established fibrosis in a preclinical model of cardiac fibrosis by VIP
Oct 29, 2015: ProMetic’s PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Myocardial Fibrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Myocardial Fibrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Myocardial Fibrosis - Pipeline by Evotec SE, H1 2020
Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2020
Myocardial Fibrosis - Pipeline by Haya Therapeutics, H1 2020
Myocardial Fibrosis - Pipeline by Invivosciences Inc, H1 2020
Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, H1 2020
Myocardial Fibrosis - Pipeline by Liminal BioSciences Inc, H1 2020
Myocardial Fibrosis - Pipeline by MandalMed Inc, H1 2020
Myocardial Fibrosis - Pipeline by NovoMedix LLC, H1 2020
Myocardial Fibrosis - Pipeline by Palatin Technologies Inc, H1 2020
Myocardial Fibrosis - Pipeline by Pharmaxis Ltd, H1 2020
Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H1 2020
Myocardial Fibrosis - Pipeline by Vectus Biosystems Ltd, H1 2020
Myocardial Fibrosis - Dormant Projects, H1 2020
Myocardial Fibrosis - Discontinued Products, H1 2020